Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 29.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 376,244 shares of the biotechnology company’s stock after purchasing an additional 86,522 shares during the quarter. Quinn Opportunity Partners LLC’s holdings in Sarepta Therapeutics were worth $7,250,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of SRPT. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock valued at $208,452,000 after purchasing an additional 1,657,267 shares during the period. Erste Asset Management GmbH boosted its stake in shares of Sarepta Therapeutics by 65.7% during the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock worth $50,588,000 after buying an additional 1,064,530 shares during the period. Aberdeen Group plc grew its holdings in shares of Sarepta Therapeutics by 59.6% during the third quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock worth $38,208,000 after buying an additional 740,360 shares during the last quarter. First Trust Advisors LP increased its position in Sarepta Therapeutics by 209.1% in the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock valued at $37,380,000 after acquiring an additional 1,312,220 shares during the period. Finally, Geode Capital Management LLC increased its position in Sarepta Therapeutics by 3.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock valued at $32,085,000 after acquiring an additional 55,076 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the transaction, the director directly owned 1,765 shares of the company’s stock, valued at $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of recent research reports. Wells Fargo & Company decreased their price objective on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Wall Street Zen raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Royal Bank Of Canada upped their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 8th. Loop Capital set a $25.00 price target on Sarepta Therapeutics in a report on Tuesday, March 3rd. Finally, Barclays began coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 price objective on the stock. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $32.15.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $16.40 on Friday. The company has a market cap of $1.72 billion, a P/E ratio of -1.94, a price-to-earnings-growth ratio of 0.25 and a beta of 0.42. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $103.32. The business has a fifty day moving average of $19.43 and a two-hundred day moving average of $19.98. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. During the same period last year, the company earned $1.90 earnings per share. The business’s revenue for the quarter was down 32.7% compared to the same quarter last year. As a group, analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.